Healthcare entity
market-trends is the sole category represented across all 3 tracked stories. Across a 165-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Each story carries 5.3 original sources on average, compared with 3.7 for the broader beat in this window.
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 3 tracked stories. Across a 165-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Each story carries 5.3 original sources on average, compared with 3.7 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6 for that window. GSK is the most frequent co-covered peer, appearing in 1 of the 3 tracked stories. This profile follows 3 Healthcare stories mentioning Collegium Pharmaceutical across the period from February 26, 2026 to August 9, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 964 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Collegium Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Source: manilatimes.net · manilatimes.net
Collegium Pharmaceutical is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
